Quarterly report pursuant to Section 13 or 15(d)

Related Party Transaction - Additional Information (Detail)

v3.10.0.1
Related Party Transaction - Additional Information (Detail)
6 Months Ended 9 Months Ended 12 Months Ended 16 Months Ended 20 Months Ended
Jul. 24, 2017
USD ($)
$ / shares
shares
Jul. 20, 2017
USD ($)
shares
Jul. 19, 2017
USD ($)
shares
Jul. 18, 2017
USD ($)
$ / shares
shares
Mar. 07, 2017
USD ($)
Sep. 30, 2015
USD ($)
$ / shares
shares
May 18, 2015
USD ($)
Jun. 30, 2018
USD ($)
$ / shares
Sep. 30, 2016
USD ($)
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
NotesPayable
Dec. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
May 23, 2018
$ / shares
Jul. 31, 2017
USD ($)
Related Party Transaction [Line Items]                              
Common stock, par value | $ / shares               $ 0.001   $ 0.001       $ 0.001  
Ricanto, Ltd [Member]                              
Related Party Transaction [Line Items]                              
Consulting fees incurred, related parties                 $ 100,000 $ 0          
Related party consulting agreement, date of termination               Aug. 01, 2017              
Accounts payable, related parties       $ 600,000       $ 0     $ 600,000 $ 600,000 $ 600,000    
Shares issued to related party for services | shares       475                      
Shares issued to related party, par value | $ / shares       $ 0.01                      
Ricanto, Ltd [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                              
Related Party Transaction [Line Items]                              
Number of shares post-conversion | shares       17,067                      
Chief Executive Officer [Member]                              
Related Party Transaction [Line Items]                              
Accounts payable, related parties               0              
Notes payable, related parties                     $ 200,000 200,000 200,000    
Number of notes payable | NotesPayable                     2        
Notes payable, rate of interest                     3.50%        
Notes payable repayment period                     1 year        
Outstanding principal, included in shareholder loans                     $ 200,000 200,000 200,000    
Accrued interest owed to related party               0     3,000 3,000 3,000    
Salary paid                         0    
Chief Executive Officer [Member] | Accrued Compensation [Member]                              
Related Party Transaction [Line Items]                              
Salary paid     $ 400,000                        
Accrued salaries                     700,000 700,000 700,000    
Accrued salaries, common stock shares issued | shares     238                        
Percentage of common stock issued in settlement of accrued salaries     50.00%                        
Percentage of cash payment in settlement of accrued salaries     50.00%                        
Chief Executive Officer [Member] | Convertible Notes Payable [Member]                              
Related Party Transaction [Line Items]                              
Shares issued to related party, par value | $ / shares $ 0.01                            
Debt conversion, converted instrument, amount $ 200,000                            
Debt conversion, converted instrument, shares issued | shares 146                            
Chief Executive Officer [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                              
Related Party Transaction [Line Items]                              
Number of shares post-conversion | shares 5,246   8,551                        
Lender                              
Related Party Transaction [Line Items]                              
Accounts payable, related parties               0     700,000 700,000 700,000    
Notes payable, related parties         $ 20,000                    
Notes payable, rate of interest         3.50%                    
Notes payable repayment period         1 year                    
Accrued interest owed to related party               0     35,000 35,000 35,000    
Debt conversion, converted instrument, amount $ 800,000                            
Debt conversion, converted instrument, shares issued | shares 586                            
Common stock, par value | $ / shares $ 0.01                            
Lender | Convertible Promissory Note [Member]                              
Related Party Transaction [Line Items]                              
Notes payable, related parties             $ 2,700,000                
Notes payable, rate of interest             3.50%                
Debt conversion, converted instrument, amount           $ 2,000,000                  
Debt conversion, converted instrument, shares issued | shares           4,500                  
Common stock, par value | $ / shares           $ 0.01                  
Lender | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                              
Related Party Transaction [Line Items]                              
Number of shares post-conversion | shares 182,743                            
Chief Financial Officer [Member]                              
Related Party Transaction [Line Items]                              
Accounts payable, related parties               0              
Accrued interest owed to related party               0              
Salary paid                       0      
Chief Financial Officer [Member] | Accrued Compensation [Member]                              
Related Party Transaction [Line Items]                              
Salary paid   $ 200,000                          
Accrued salaries                     $ 300,000 $ 300,000 $ 300,000    
Accrued salaries, common stock shares issued | shares   127                          
Percentage of common stock issued in settlement of accrued salaries   50.00%                          
Percentage of cash payment in settlement of accrued salaries   50.00%                          
Chief Financial Officer [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Common Stock                              
Related Party Transaction [Line Items]                              
Number of shares post-conversion | shares   4,563                          
Michelle Griffin [Member] | OncoGenex Pharmaceuticals, Inc [Member]                              
Related Party Transaction [Line Items]                              
Termination fee payable                             $ 600,000
Michelle Griffin [Member] | OncoGenex Pharmaceuticals, Inc [Member] | Accrued Liabilities Other [Member]                              
Related Party Transaction [Line Items]                              
Accounts payable, related parties               $ 0